Teva’s recent US Food and Drug Administration approval for a generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) has not discouraged Hikma’s expectations of strong results for its own generic in 2022, according to Hikma CEO Siggi Olafsson.
Speaking at the J.P. Morgan Healthcare Conference, Olafsson highlighted Hikma’s Advair generic – which was launched in full last April,...




